Table 2 Clinical data for patients who underwent neoadjuvant therapy
n | M30 positive DTC | p-value | |
|---|---|---|---|
N = 85 | (%) | ||
Total | 85 | 41 (48) | |
Menopausal status | n.s. | ||
Premenopausal | 48 | 20 (42) | |
Postmenopausal | 37 | 21 (57) | |
Tumor size | n.s. | ||
ypT0 | 19 | 12 (63) | |
ypT1 | 31 | 13 (42) | |
ypT2-4 | 35 | 16 (46) | |
Nodal status | 0.007 | ||
ypN negative | 39 | 25 (64) | |
ypN positive | 46 | 16 (35) | |
Histology | n.s. | ||
Ductal | 66 | 32 (49) | |
Lobular | 15 | 7 (47) | |
Others | 4 | 2 (50) | |
Grading | n.s. | ||
I/II | 67 | 34 (50) | |
III | 18 | 7 (39) | |
ER status | n.s. | ||
Negative | 28 | 15 (54) | |
Positive | 57 | 26 (46) | |
PR status | n.s. | ||
Negative | 27 | 17 (63) | |
Positive | 58 | 24 (41) | |
HER2 status | n.s. | ||
Negative | 66 | 31 (47) | |
Positive | 19 | 10 (53) |